Just How Flexible Can a Prospective Clinical Trial Be? Donald A. Berry Donald A. Berry

Slides:



Advertisements
Similar presentations
Slide 1 Insert your own content. Slide 2 Insert your own content.
Advertisements

Design of Dose Response Clinical Trials
Bayesian Trial Designs: Drug Case Study Donald A. Berry Donald A. Berry
Labeling claims for patient- reported outcomes (A regulatory perspective) FDA/Industry Workshop Washington, DC September 16, 2005 Lisa A. Kammerman, Ph.D.
Matthew M. Riggs, Ph.D. metrum research group LLC
1 adaptive design working group PhRMA adaptive design working group on behalf of Keaven Anderson Suman Bhattacharya Alun Bedding.
Flexible designs for pivotal clinical trials Vlad Dragalin, RSU-SDS-BDS-GSK FDA/Industry Workshop Session: Flexible Designs – Are We Ready Yet? Washington,
A Practical Approach to Accelerating the Clinical Development Process Jerald S. Schindler, Dr.P.H. Assistant Vice President Global Biostatistics & Clinical.
BAYESIAN ADAPTIVE DESIGN & INTERIM ANALYSIS Donald A. Berry Donald A. Berry
The Application of Propensity Score Analysis to Non-randomized Medical Device Clinical Studies: A Regulatory Perspective Lilly Yue, Ph.D.* CDRH, FDA,
1 FDA Industry Workshop Statistics in the FDA & Industry The Future David L DeMets, PhD Department of Biostatistics & Medical Informatics University of.
Combining Like Terms. Only combine terms that are exactly the same!! Whats the same mean? –If numbers have a variable, then you can combine only ones.
0 - 0.
Teacher Name Class / Subject Date A:B: Write an answer here #1 Write your question Here C:D: Write an answer here.
CS4026 Formal Models of Computation Running Haskell Programs – power.
Experimental and Quasiexperimental Designs Chapter 10 Copyright © 2009 Elsevier Canada, a division of Reed Elsevier Canada, Ltd.
A Clean Hand Device for Manual Wheelchairs March 4, 2004.
Panel Discussion 1 George Williams Amgen. Barbara Tilley - Sample Size Estimation… Key point – considering both short term benefit of symptomatic treatment.
Phase II/III Design: Case Study
Community Clinical Oncology Program (CCOP) Updated: July 2006 Role of Data Safety Monitoring Board (DSMB) Mira Shah, CIM, CCRP March 2011.
Clinical Trials What Are They and When Are They Right For You? Maura N. Dickler Assistant Attending Physician Breast Cancer Medicine Service Memorial Sloan-Kettering.
IT Analytics for Symantec Endpoint Protection
T. A. LouisTrialNet Workshop March 7, The POPPI 1 Example: Statistical Comments Thomas A. Louis, PhD Department of Biostatistics Johns Hopkins Bloomberg.
Hydrological information systems Svein Taksdal Head of section, Section for Hydroinformatics Hydrology department Norwegian Water Resources and Energy.
Single-Patient Use of Investigational Drugs and Biologic Products for Treating Cancer Grant Williams, M.D. Medical Team Leader DODP/CDER/FDA.
Statistical Analysis for Two-stage Seamless Design with Different Study Endpoints Shein-Chung Chow, Duke U, Durham, NC, USA Qingshu Lu, U of Science and.
Clinical Trial Design Considerations for Therapeutic Cancer Vaccines Richard Simon, D.Sc. Chief, Biometric Research Branch, NCI
1 Statistical and Practical Aspects of a Non-Stop Drug Development Strategy Karen L. Kesler and Ronald W. Helms Rho, Inc. Contact:
Clinical Trials Medical Interventions
Turning Questions into Trials: Innovation in Surgical Oncology Jennifer E. Rosen MD FACS Assistant Professor of Surgery and Molecular Medicine Boston University.
Impact of Dose Selection Strategies on the Probability of Success in the Phase III Zoran Antonijevic Senior Director Strategic Development, Biostatistics.
Bureau of Gastroenterology, Infection
JEOPARDY! JEOPARDY! I Can’t Believe It’s Not JEOPARDY!
Adaptive Clinical Trials
Phase II Design Strategies Sally Hunsberger Ovarian Cancer Clinical Trials Planning Meeting May 29, 2009.
Clinical Trials The Way We Make Progress Against Disease.
INVESTIGATIONAL DRUG SERVICES IN THE HOSPITAL Sheree Miller, Pharm.D. University of Washington Medical Center
23 August 2015Michael Knoessl1 PhUSE 2008 Manchester / Michael Knoessl Implementing CDISC at Boehringer Ingelheim.
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
Testing People Scientifically.  Clinical trials are research studies in which people help doctors and researchers find ways to improve health care. Each.
Jasper Ogwal-Okeng Gulu University Research Workshop 3 rd -6 th March 08.
BIOE 301 Lecture Seventeen. Guest Speaker Jay Brollier World Camp Malawi.
Adaptive designs as enabler for personalized medicine
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Aligning Trial Design and Key Processes in Phase III Event Driven Trials: Protocol (via a Special Protocol Assessment), Data Monitoring Committee Charter.
How much can we adapt? An EORTC perspective Saskia Litière EORTC - Biostatistician.
Legal & Ethical Issues. Objectives At the completion of this session the participant will be able to: ◦ Describe the ethical principles associated with.
CLINICAL TRIALS IN NEW DRUG DEVELOPMENT Michael A Ross,M.D. President CPL Inc.
1 Statistics in Drug Development Mark Rothmann, Ph. D.* Division of Biometrics I Food and Drug Administration * The views expressed here are those of the.
The Use of Predictive Biomarkers in Clinical Trial Design Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute
BIOE 301 Lecture Seventeen. Progression of Heart Disease High Blood Pressure High Cholesterol Levels Atherosclerosis Ischemia Heart Attack Heart Failure.
Clinical Trials and Research A Guide for Community Advisory Board Members Participant Manual.
Lecture Twenty: Clinical Trials Biomedical Engineering for Global Health.
Enrollment and Monitoring Procedures for NCI Supported Clinical Trials Barry Anderson, MD, PhD Cancer Therapy Evaluation Program National Cancer Institute.
European Patients’ Academy on Therapeutic Innovation Principles of New Trial Designs.
Pharmacy & The IRB Linda Sailor, BS, PharmD Rania Sadaka, BS, PharmD May 2015.
Phase III Clinical Trial of FOLFOX with or without Cetuximab in Resected Stage 3 Colon Cancer: Cooperative Group Trial N0147 (NCCTG*,
Is a Clinical Trial Right for Me?
Statistical Approaches to Support Device Innovation- FDA View
Clinical Trials Medical Interventions
Strategies for Implementing Flexible Clinical Trials Jerald S. Schindler, Dr.P.H. Cytel Pharmaceutical Research Services 2006 FDA/Industry Statistics Workshop.
Data Monitoring Committees: Current Issues and Challenges Some Discussion Points Jim Neaton University of Minnesota.
Clinical Trials.
Is a Clinical Trial Right for Me?
Khine Zaw Oo Defence Services Medical Research Centre Myanmar
Statistical considerations for the Nipah virus treatment study
Data Monitoring committees and adaptive decision-making
Statistical considerations for the Nipah virus treatment study
Bioengineering and World Health
Finding a Balance of Synergy and Flexibility in Master Protocols
Presentation transcript:

Just How Flexible Can a Prospective Clinical Trial Be? Donald A. Berry Donald A. Berry

2 2 Definition of flexible l Pliant l Characterized by a ready capability to adapt to new, different, or changing requirements l Pliant l Characterized by a ready capability to adapt to new, different, or changing requirements

3 3 With thanks to Mike Krams & Vlad Dragalin

4 4 Original question is not helpful Two kinds of flexibility: l Ad hoc (improvised) l Planned (prospective) Two kinds of flexibility: l Ad hoc (improvised) l Planned (prospective)

5 5 Original question is not helpful Two kinds of flexibility: l Ad hoc: okay for personal or internal company decisions l Planned: essential for external buy-in Two kinds of flexibility: l Ad hoc: okay for personal or internal company decisions l Planned: essential for external buy-in

6 6 New question 1: How to deal with ad hoc flexibility in a clinical trial? You cant!

7 7 New question 2: How to deal with planned flexibility in a clinical trial? l Design l The team on board? l Logistics l Regulatory l Design l The team on board? l Logistics l Regulatory

8 8 Design l Modeling--arbitrarily complicated l Efficacy and safety l Computation l OCs & comparisons n Type I error n Power n Sample size n Alternative designs l Modeling--arbitrarily complicated l Efficacy and safety l Computation l OCs & comparisons n Type I error n Power n Sample size n Alternative designs

9 9 The team on board? l You have to teach them l And you have to keep teaching them! l I dont want the DSMB making decisions such as whether to go to phase III. l DSMB as automaton l You have to teach them l And you have to keep teaching them! l I dont want the DSMB making decisions such as whether to go to phase III. l DSMB as automaton

10 Logistics l Data flow: Updating database l Clean data? (no, but model) n QA n Auxiliary variables n Central review l Missing data--same as above l What CRO? l Information leakage--who knows what and when? l Data flow: Updating database l Clean data? (no, but model) n QA n Auxiliary variables n Central review l Missing data--same as above l What CRO? l Information leakage--who knows what and when?

11 Logistics (contd) Adaptive design is a whole new ball game. If you dont know what you are doing, you can do some very bad things and damage the integrity of the trial, and of the whole process.

12 Who knows what & when? l Phase I or II vs Phase III l Dose-finding (The Pharmacist Knows) l Dropping arms or adaptive randomization (blinded vs open) l Seamless phase II/III n Simple line in the sand (Publish but continue to accrue?) n End of phase II meeting n Expanding accrual n One study or two? l Phase I or II vs Phase III l Dose-finding (The Pharmacist Knows) l Dropping arms or adaptive randomization (blinded vs open) l Seamless phase II/III n Simple line in the sand (Publish but continue to accrue?) n End of phase II meeting n Expanding accrual n One study or two?

13 Regulatory l CRCs and IRBs n Please explain in lay terms (Examples, examples, examples) n Informed consent? l FDA, EMEA n Meet early & as often as possible l CRCs and IRBs n Please explain in lay terms (Examples, examples, examples) n Informed consent? l FDA, EMEA n Meet early & as often as possible

14 The Bottom Line l Clinical trials will continue to become more complicated (such as I-SPY2) l This is good and bad l Trials must begin to address interactions between treatments and patient covariates l Clinical trials will continue to become more complicated (such as I-SPY2) l This is good and bad l Trials must begin to address interactions between treatments and patient covariates

15 The Bottom Line l Traditional trials are poorly suited for identifying treatments that benefit patients who have hetero- geneous diseases such as cancer l The adaptive path is treacherous, with mines every step of the way l Avoiding mines is challenging, but enormously rewarding... and fun! l Traditional trials are poorly suited for identifying treatments that benefit patients who have hetero- geneous diseases such as cancer l The adaptive path is treacherous, with mines every step of the way l Avoiding mines is challenging, but enormously rewarding... and fun!